Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 5Lymphoid 3Other hematologic neoplasm 2Breast 2Tumor-Agnostic 1Thoracic 1Other 1Gynecologic 1Genitourinary 1Endocrine 1Dermatologic 1CNS 1

Conditions

Obesity 1Multiple Endocrine Neoplasia Type 1 1Motor Activity 1

Interventions

lutetium Lu 177 dotatate 30Magnetic Resonance Spectroscopy 25pembrolizumab 21Specimen Handling 18Nivolumab 17cabozantinib 14lenvatinib 12Everolimus 12trametinib 11gallium Ga 68 dotatate 10dabrafenib 10Ipilimumab 10Carboplatin 10Cisplatin 8atezolizumab 7Temozolomide 7Lutetium-177 7X-Rays 6Etoposide 6Capecitabine 6surufatinib 5lanreotide 5fluorodopa F 18 5cemiplimab 5Vemurafenib 5Paclitaxel 5Octreotide 5Lutetium 5Fluorodeoxyglucose F18 5Disulfides 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Diet × Endocrine × 1 year × Clear all
NCT04175678 2026-03-10

Project 1: Diet and Exercise Modulate the Sperm Epigenome in Men

Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center

Phase NA Active not recruiting
100 enrolled
EndocrineOther

Motor Activity, Obesity, Multiple Endocrine Neoplasia Type 1

Data powered by HemOnc (CC BY 4.0) Colophon âš¡